Gradient Denervation Technologies develops a medical device for a transvascular treatment of pulmonary hypertension.
Gradient Denervation Technologies has raised $15.0M in total funding. The most recent round was Series A. The last funding was announced in September 2023.
Gradient Denervation Technologies's investors include Asabys Partners, Sofinnova Partners, Thuja Capital, MD Start, MedTech Innovator.
Gradient Denervation Technologies is headquartered in Paris, France.
Gradient Denervation Technologies develops a medical device for a transvascular treatment of pulmonary hypertension.
Gradient Denervation Technologies is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Gradient Denervation Technologies — Funding & Investors." VCBacked, September 7, 2023, https://www.vcbacked.co/company/gradient-denervation-technologies. Accessed July 22, 2026.
VCBacked. (2023). Gradient Denervation Technologies — Funding & Investors. Retrieved July 22, 2026, from https://www.vcbacked.co/company/gradient-denervation-technologies
{{cite web |title=Gradient Denervation Technologies — Funding & Investors |url=https://www.vcbacked.co/company/gradient-denervation-technologies |website=VCBacked |access-date=July 22, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated